[The role of heparin in prevention of deep veins thrombosis and pulmonary artery thromboembolism in therapeutic regime patients].
The author reviews available literature on occurrence and effectiveness of prevention of deep vein thrombosis (DVT) and pulmonary artery thromboembolism (PAT) in therapeutic patients, MEDINOX trial, in particular. The latter trial has established that enoxaparine in a dose 40 mg/day for 6-14 days decreases the risk of DVT/PAT by 63% in inpatients.
Panchenko
E P
EP
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011651:Pulmonary Artery / Q000473:pathology*; D012720:Severity of Illness Index; D013923:Thromboembolism / Q000175:diagnosis / Q000517:prevention & control*; D013997:Time Factors; D020246:Venous Thrombosis / Q000175:diagnosis / Q000517:prevention & control*
D000925:Anticoagulants; D017984:Enoxaparin; D006493:Heparin